1. Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
- Author
-
Zhang, Jian, McAndrew, Nicholas P, Wang, Xiaojia, Du, Yiqun, DiCarlo, Brian, Wang, Mei, Chen, Kan, Yu, Wenlei, and Hu, Xichun
- Subjects
Blood-Brain Barrier ,Animals ,Humans ,Mice ,Breast Neoplasms ,Central Nervous System Neoplasms ,Receptor ,erbB-2 ,Antineoplastic Combined Chemotherapy Protocols ,Protein Kinase Inhibitors ,Female ,Blood–brain barrier ,Breast cancer ,Central nervous system metastases ,HER2 ,Tyrosine kinase inhibitor ,Receptor ,ErbB-2 ,Breast Cancer ,Cancer ,Clinical Research ,Neurosciences ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Blood-brain barrier ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundPatients with HER2-positive metastatic breast cancer (MBC) are at high risk of developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor with good blood-brain barrier (BBB) penetration is highly desirable.MethodsThe design and structure-activity relationship of DZD1516 was described. The potency and selectivity of DZD1516 were determined by enzymatic and cellular assays. The antitumor activity of DZD1516 monotherapy or in combination with HER2 antibody-drug conjugate was assessed in CNS and subcutaneous xenograft mouse models. A phase 1 first-in-human study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DZD1516 in patients with HER2+ MBC who relapsed from standard of care.ResultsDZD1516 showed good selectivity against HER2 over wild-type EGFR in vitro and potent antitumor activity in vivo. Twenty-three patients were enrolled and received DZD1516 monotherapy treatment across six dose levels (25-300 mg, twice daily). Dose-limiting toxicities were reported at 300 mg, and thus 250 mg was defined as the maximum tolerated dose. The most common adverse events included headache, vomiting, and hemoglobin decreased. No diarrhea or skin rash was observed at ≤ 250 mg. The mean Kp,uu,CSF was 2.1 for DZD1516 and 0.76 for its active metabolite DZ2678. With median seven lines of prior systemic therapy, the best antitumor efficacy in intracranial, extracranial and overall lesions was stable disease.ConclusionsDZD1516 provides positive proof of concept for an optimal HER2 inhibitor with high BBB penetration and HER2 selectivity. Further clinical evaluation of DZD1516 is warranted, with the RP2D being 250 mg BID.Clinicaltrialsgov identifier NCT04509596. Registered on August 12, 2020; Chinadrugtrial: CTR20202424 Registered on December 18, 2020.
- Published
- 2023